CAJ | 학술논문

目的：分析比较近距离125 I粒子置入联合间歇性内分泌疗法( intermittent hormonal therapy, IHT)在局限性前列腺癌治疗中的效果。方法回顾2003年1月至2013年7月期间未接受根治性前列腺切除而接受治疗满5年的136例局限性前列腺癌患者,按治疗方式分为单纯间歇性内分泌治疗( A组,46例)、单纯近距离125 I粒子置入( B组,42例)和近距离125 I粒子置入+间歇性内分泌治疗( C组,48例)三组,分析比较三组患者的治疗无效率、5年无事件生存率和5年生存率。结果 A组、 B组、 C组治疗无效率分别为17.39%、16.67%、2.08%,5年无事件生存率分别为36.96%、66.67%、87.50%,5年生存率分别为50.00%、73.81%、93.75%。 C组的治疗无效率明显低于A组和B组,差异有统计学意义( P<0.05)； C组的5年无事件生存率和5年生存率明显高于A组和B组,差异均有统计学意义( P<0.05)； C组的不良反应发生率明显低于B组,差异有统计学意义( P<0.05)。结论近距离125 I粒子置入联合间歇性内分泌治疗作为局限性前列腺癌的综合治疗手段,可以增加治疗有效率、提高无事件生存率和生存率,是局限性前列腺癌安全有效的治疗方法。
목적：분석비교근거리125 I입자치입연합간헐성내분비요법( intermittent hormonal therapy, IHT)재국한성전렬선암치료중적효과。방법회고2003년1월지2013년7월기간미접수근치성전렬선절제이접수치료만5년적136례국한성전렬선암환자,안치료방식분위단순간헐성내분비치료( A조,46례)、단순근거리125 I입자치입( B조,42례)화근거리125 I입자치입+간헐성내분비치료( C조,48례)삼조,분석비교삼조환자적치료무효솔、5년무사건생존솔화5년생존솔。결과 A조、 B조、 C조치료무효솔분별위17.39%、16.67%、2.08%,5년무사건생존솔분별위36.96%、66.67%、87.50%,5년생존솔분별위50.00%、73.81%、93.75%。 C조적치료무효솔명현저우A조화B조,차이유통계학의의( P<0.05)； C조적5년무사건생존솔화5년생존솔명현고우A조화B조,차이균유통계학의의( P<0.05)； C조적불량반응발생솔명현저우B조,차이유통계학의의( P<0.05)。결론근거리125 I입자치입연합간헐성내분비치료작위국한성전렬선암적종합치료수단,가이증가치료유효솔、제고무사건생존솔화생존솔,시국한성전렬선암안전유효적치료방법。
Objective To investigate the clinical therapeutic effect of the combining of intermittent endocrine therapy and brachytherapy in localized prostate cancer. Method A total of 136 localized prostate cancer patients who had received 5-year treatment without radical prostatectomy from January 2003 to July 2013 were retrospectively analyzed. All patients were divided into three groups based on therapy: A group ( 46 cases ) received intermittent endocrine therapy; B group ( 42 cases) accepted 125 I brachytherapy;And C group ( 48 cases) was applied with 125 I brachytherapy+intermittent endo-crine therapy. And the inefficiency, 5-year event-free survival rate and 5-year overall survival rate of the three groups were compared. Result The inefficiency in A group, B group, C group was 17.39%, 16.67%, 2.08%, while 5-year event-free survival rate was 36.96%, 66.67%, 87.50%, and 5-year survival rate was 50.00%, 73.81%, 93.75%, respectively. The inefficiency of C was lower than A and B ( P<0.05) , but the 5-year event-free survival rate and 5-year survival rate in C were statistically better than A and B ( P<0.05);And the adverse reaction in C was statistically less than B ( P<0.05 ) . Conclusion As a comprehensive therapy, the combination of intermittent endocrine therapy and 125 I brachytherapy can increase response rate, event-free survival rate and overall survival rate, and is an effective and safe treatment for localized prostate cancer.